Allergia, Inc. v. Bouboulis

229 F. Supp. 3d 1150, 2017 U.S. Dist. LEXIS 7759, 2017 WL 238368
CourtDistrict Court, S.D. California
DecidedJanuary 19, 2017
DocketCase No.: 14-CV-1566 JLS (RBB)
StatusPublished
Cited by2 cases

This text of 229 F. Supp. 3d 1150 (Allergia, Inc. v. Bouboulis) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Allergia, Inc. v. Bouboulis, 229 F. Supp. 3d 1150, 2017 U.S. Dist. LEXIS 7759, 2017 WL 238368 (S.D. Cal. 2017).

Opinion

ORDER DENYING DEFENDANT’S MOTION FOR ADVANCEMENT OF LEGAL EXPENSES

(ECF No. 59)

Hon. Janis L. Sammartino, United States District Judge

Presently before the Court is Defendant Denis Bouboulis’ Motion for Advancement of Legal Expenses. (“Mot.,” ECF No. 59.) Also before the Court is Plaintiff Allergia, Inc.’s Response in Opposition to, (“Opp’n,” ECF No. 62), and Defendant’s Reply in Support of, (“Reply,” ECF No. 64), Defendant’s Motion. Plaintiff also filed an untimely supplemental response in opposition. (“Supp. Opp’n,” ECF No. 63.) The Court vacated the hearing on the Motion scheduled for August 25, 2016 pursuant to Civil Local Rule 7.1(d)(1). (ECF No. 65.) After considering the parties’ arguments and the law, the Court DENIES Defendant’s Motion for Advancement of Legal Expenses.

BACKGROUND

Beginning several years ago, Defendant worked with Plaintiffs predeeessor-in-in-terest, CLRS Technology, Inc., to develop and invent medical devices and related methods for using phototherapeutics to alleviate the symptoms of allergic rhinitis. (Second Amended Complaint (“SAC”) ¶ 9, ECF No. 53.) In exchange for these contributions, Defendant received 116,111 shares of CLRS common stock. (Id.)

On August 5, 2010, CLRS filed a provisional patent application with the United States Patent and Trademark Office (USP-TO), Application Ser. No. 61/371,172 (the “’172 Application”), directed to an invention for alleviating the symptoms of allergic rhinitis. (Id. ¶ 10.) Defendant was one of three named inventors. (Id.)

Approximately two months later, CLRS spun out ownership of the ’172 Application to Plaintiff in connection with a corporate transaction involving a third party, Solta. (Id. ¶ 11.) Accordingly, Plaintiff was incorporated on October 5, 2010 under the laws of California. (Id. ¶ 12.) All of the then-existing shareholders of CLRS—including Defendant—received shares of stock in Plaintiff based on their then-existing shares in CLRS. (Id.) Defendant was made Plaintiffs President. (See id. ¶ 16.)

[1152]*1152CLRS then assigned all its rights in the ’172 Application to Plaintiff. (Id. ¶ 13.) On October 12, 2010, Defendant signed the Assignment and Assumption Agreement (the “Assignment Agreement”) on behalf of Plaintiff. (Id. ¶¶ 14-15.) The Assignment Agreement provided that “Assignor [CLRS] owns all of the assets set forth on Exhibit A attached hereto (the “Distributed Assets”) ... [,] ” (id. ¶ 15(a) (emphasis in original)), which included the '172 Application, (id. ¶ 15(d)). Pursuant to the Assignment Agreement, CLRS and Plaintiff desired to effect “the sale, assignment, transfer, conveyance, distribution and delivery of all of Assignor’s rights, title and interest in, to or under the Distributed Assets to Assignee [... Allergia]” and, “at the request of a party [to the Agreement] and without further consideration, the other party ... shall execute and deliver ... such other instruments of assignment ... as such party may reasonably request to effect the distribution by [CLRS] of the Distributed Assets.” (Id. at ¶¶ 15(b), (c)). On October 13, 2010, Defendant also signed the License Agreement on behalf of Plaintiff. (Id. at ¶¶ 16-17.) The License Agreement expressly represented that CLRS “hereby assigned to [Plaintiff] all right, title and interest in and to the ATD Patent Rights,” which was defined as including the 172 Application. (Id. ¶¶ 17(a), (c).)

When signing the Assignment and License Agreements, “Defendant was fully aware of the contents of the documents ..., and was fully aware of the purpose and intent of those documents.” (Id. ¶ 18.) “Defendant gave no indication to Plaintiff ... that Defendant believed that CLRS and then [Plaintiff] did not own all of the 172 [Application] and related rights, and/or that Defendant believed that he had not assigned his rights therein to CLRS and then/thereby to [Plaintiff].” (Id. ¶ 19.) Indeed, “for at least many months ..., Defendant ... did not tell or indicate to [Plaintiff] ... that Defendant ... believed that he personally retained any ownership in the 172- [Application] and related rights,” but rather he “remained silent on the issue.” (Id. ¶ 24.)

On October 15, 2010, the initial incorpo-rator of Plaintiff formally named Defendant as an initial director of Plaintiff. (Id. ¶ 20.) On that same date, the CLRS/Solta transaction was execute. (Id. ¶ 21.) The resulting Agreement and Plan of Merger (the Executive Summary) and Disclosure Schedule expressly referenced the Assignment and License Agreements. (Id. ¶¶ 21-22.)

A few months later, Defendant requested a telephone conference with the owners and directors of Plaintiff, during which he disclosed an outline of a strategic business plan for Plaintiff. (Id. ¶ 27.) Defendant proposed that he would undertake execution of the proposed plan and assume the duties of CEO of Plaintiff if he were granted a controlling stake in the capital stock of Plaintiff. (Id.) In response, the shareholders and directors of Plaintiff requested that Defendant prepare and present a budget for his proposal. (Id. ¶ 28.) Several months passed without Defendant making the requested presentation. (Id.) Instead, Defendant “secretly prepared a related and apparently competitiye patent application ... without the knowledge and/or authorization of [Plaintiff] or its other shareholders.” (Id. ¶ 29.) Defendant continued as President and director of Plaintiff until approximately May 2011. (Id. ¶ 30.)

On August 4, 2011, Plaintiff filed a full utility application, Ser. No. 13/198,672 (the “’672 Application”). (Id. ¶ 34.) Although Plaintiff solicited Defendant’s signature on related filings, Defendant refused to participate or assist in the prosecution of the ’672 Application. (Id.)

On August 5, 2011, Defendant secretly filed Application Ser. No. US 13/204,282 [1153]*1153(the ’282 Application). (Id. ¶¶ 29, 35.) The ’282 Application “is so closely related to [the '172 Application] that it may fore-seeably interfere with or negatively affect [Plaintiffl’s business efforts related to [PlaintifQ’s patent-pending technology.” (Id. ¶ 29.) Defendant filed a related Patent Cooperation Treaty patent application, Ser. No. PCT/US12/049108 (the “’108 Application”), on August 1, 2012, and a related European Union application, Ser. No. 2,739,354 (the “’354 Application”), on February 26, 2014. (Id. ¶ 36.) “Defendant’s patent applications include description and claims that are similar or even virtually identical to the description and claims ... in the Plaintiffs pending patent applications.” (Id. ¶ 37.)

Plaintiff subsequently has “continued to make reasonable efforts to get Defendant to sign certain formal ‘assignment’ documents related to the ’172 [Application],” but Defendant has refused. (Id. ¶ 39.) “[Potential investors in Plaintiffs ’172 patent-pending technologies and related opportunities have declined to invest based on Defendants] ... actions, including positions taken and communicated to those investors by Defendant ... regarding the parties’ respective rights regarding Plaintiffs ’172 patent-pending technologies and related opportunities.” (Id. ¶ 40.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

David Goldman v. LBG Real Estate Companies, LLC
Court of Chancery of Delaware, 2024
Richmond v. Mikkelson CA4/1
California Court of Appeal, 2021

Cite This Page — Counsel Stack

Bluebook (online)
229 F. Supp. 3d 1150, 2017 U.S. Dist. LEXIS 7759, 2017 WL 238368, Counsel Stack Legal Research, https://law.counselstack.com/opinion/allergia-inc-v-bouboulis-casd-2017.